Advertisement

Palliative Management of Breathlessness

  • David CurrowEmail author
  • Diana Ferreira
Reference work entry

Abstract

Breathlessness is pervasive in late stage disease both because of the disease itself, comorbidities, and cachexia. Given its high prevalence, it is sad that the options for symptomatic treatment (having optimized the management of underlying cause(s)) is so small. Careful assessment of potentially reversible causes contributing to breathlessness is paramount. Nonpharmacological interventions have a relatively strong evidence base as does regular, low dose, extended release oral morphine. There is a need for ongoing research into this pervasive and frightening symptom given the impact it has on patients, their caregivers, and health professionals.

Notes

Disclosures

DCC – Consultancy to, and intellectual property payments from Mayne Pharma Pty Ltd; advisory board roles with Helsinn Pharmaceuticals and Specialist Therapeutics.

References

  1. Abernethy AP, McDonald CF, Frith PA, Clark K, Herndon JE, Marcello J, Young IH, Bull J, Wilcock A, Booth S, Wheeler JL. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet. 2010;376(9743): 784–93.CrossRefGoogle Scholar
  2. Allard P, Lamontagne C, Bernard P, Tremblay C. How effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients? A randomized continuous sequential clinical trial. J Pain Symptom Manag. 1999;17(4):256–65.CrossRefGoogle Scholar
  3. Austroads. Assessing fitness to drive for commercial and private vehicle owners – March 2012 as amended up to 30 June 2014. https://www.onlinepublications.austroads.com.au/items/AP-G56-13. Accessed 19 Mar 2018.
  4. Banzett RB, Mulnier HE, Murphy K, Rosen SD, Wise RJ, Adams L. Breathlessness in humans activates insular cortex. Neuroreport. 2000;11(10):2117–20.CrossRefGoogle Scholar
  5. Banzett RB, O’Donnell CR, Guilfoyle TE, Parshall MB, Schwartzstein RM, Meek PM, Gracely RH, Lansing RW. Multidimensional dyspnea profile: an instrument for clinical and laboratory research. Eur Respir J. 2015;45(6):1681–91.CrossRefGoogle Scholar
  6. Bausewein C, Booth S, Gysels M, Higginson I. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database Syst Rev. 2008;16(2):CD005623.  https://doi.org/10.1002/14651858.CD005623.pub2.CrossRefGoogle Scholar
  7. Chihuri S, Mielenz TJ, Dimaggio CJ, et al. Driving cessation and health outcomes in older adults. J Am Geriatr Soc. 2016;64(2):332–41.CrossRefGoogle Scholar
  8. Collier A, Rowett D, Allcroft P, Greene A, Currow DC. Academic detailing of general practitioners by a respiratory physician for diagnosis and management of refractory breathlessness: a randomised pilot study. BMC Health Serv Res. 2015;15:193.CrossRefGoogle Scholar
  9. Collier A, Litster C, Phillip JL, Agar M, Breaden K, Currow DC. Caregivers’ perspectives on the use of long term oxygen therapy for the treatment of refractory breathlessness: a qualitative study. J Pain Symptom Manag. 2017;53(1):33–9.CrossRefGoogle Scholar
  10. Currow DC, Agar M, Smith J, Abernethy A. Does palliative home oxygen improve dyspnoea? A consecutive cohort study. Palliat Med. 2009;23(4):309–16.CrossRefGoogle Scholar
  11. Currow DC, McDonald C, Oaten S, Kenny B, Allcroft P, Frith P, Briffa M, Johnson MJ, Abernethy AP. Once-daily opioids for chronic dyspnoea: a dose increment and pharmacovigilance study. J Pain Symptom Manag. 2011;42(3):388–99.CrossRefGoogle Scholar
  12. Currow DC, Clark K, Mitchell GK, Johnson MJ, Abernethy AP. Prospectively collected characteristics of adult patients, their consultations and outcomes as they report breathlessness when presenting to general practice in Australia. PLoS One. 2013a;8(9):e74814.CrossRefGoogle Scholar
  13. Currow DC, Quinn S, Greene A, Bull J, Johnson MJ, Abernethy AP. The longitudinal pattern of response when morphine is used to treat chronic refractory dyspnea. J Palliat Med. 2013b;16(8):881–6.CrossRefGoogle Scholar
  14. Currow DC, Quinn S, Ekström M, Kaasa S, Johnson MJ, Somogyi AA, Klepstad P. Can variability in the effect of opioids on refractory breathlessness be explained by genetic factors? BMJ Open. 2015;5(5):e006818.CrossRefGoogle Scholar
  15. Currow D, Ekström M, Fazekas B, Plummer J, Quinn S, McDonald C, Agar M, Clark K, Eckermann S, Abernethy A. A phase III, multi-site, randomised, double blind, placebo controlled parallel arm study of daily extended release (ER) morphine for chronic breathlessness. Abstract. In: 15th World Congress of the European Association for Palliative Care (EAPC). Madrid; 2017.Google Scholar
  16. Disler RT, Green A, Luckett T, Newton PJ, Inglis S, Currow D, Davidson PM. Experience of advanced chronic obstructive pulmonary disease: metasynthesis of existing qualitative research. J Pain Symptom Manag. 2014;48(6):1182–99.CrossRefGoogle Scholar
  17. Drug & Alcohol Services South Australia, the Flinders Medical Centre Pain Management Unit, and the Royal Adelaide Hospital Pain Management Unit with funding under the Ministerial Council on Drug Strategy Cost Shared Funding Mode. Opioid Prescription in Chronic Pain Conditions Guidelines for South Australian General Practitioners (Gps). 2008. http://www.sahealth.sa.gov.au. Accessed 19 Mar 2018.
  18. Dudgeon D, Lertzman M. Dyspnea in the advanced cancer patient. J Pain Symptom Manag. 1998;16(4):212–9.CrossRefGoogle Scholar
  19. Ekström M, Nilsson F, Abernethy AP, Currow DC. Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review. Ann Am Thoracic Soc 2015;12(7):1079–92.CrossRefGoogle Scholar
  20. Ekström M, Bajwah S, Bland JM, Currow DC, Hussain J, Johnson MJ. One evidence base; three stories: do opioids relieve chronic breathlessness? Thorax 2018;73:88–90.CrossRefGoogle Scholar
  21. Elliot MW, Adams L, Cockcroft A, MacRae KD, Murphy K, Guz A. The language of breathlessness. Use of verbal descriptors by patients with cardiopulmonary disease. Am Rev Respir Dis. 1991;144(4): 826–32.CrossRefGoogle Scholar
  22. Ferreira DH, Boland JW, Phillips JL, Lam L, Currow DC. The impact of therapeutic opioid agonists on driving-related psychomotor skills assessed by a driving simulator or an on-road driving task: a systematic review. Palliat Med. 2018;32(4):786–803.CrossRefGoogle Scholar
  23. Glaab T, Vogelmeier C, Buhl R. Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res. 2010;11:79.CrossRefGoogle Scholar
  24. Goldbart J, Yohannes AM, Woolrych R, Caton S. ‘It is not going to change his life but it has picked him up’: a qualitative study of perspectives on long term oxygen therapy for people with chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2013;11:124.CrossRefGoogle Scholar
  25. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987;42(10): 773–8.CrossRefGoogle Scholar
  26. Gysels M, Higginson IJ. The experience of breathlessness: the social course of chronic obstructive pulmonary disease. J Pain Symptom Manag. 2010;39(3):555–63.CrossRefGoogle Scholar
  27. Gysels MH, Higginson IJ. The lived experience of breathlessness and its implications for care: a qualitative comparison in cancer, COPD, heart failure and MND. BMC Palliat Care. 2011;10:15.CrossRefGoogle Scholar
  28. Herigstad M, Hayen A, Wiech K, Pattinson KT. Dyspnoea and the brain. Respir Med. 2011;105(6):809–17.CrossRefGoogle Scholar
  29. Herigstad M, Hayen A, Evans E, Hardinge FM, Davies RJ, Wiech K, Pattinson KTS. Dyspnea-related cues engage the prefrontal cortex. Chest. 2015;148(4):953–61.CrossRefGoogle Scholar
  30. Hutchinson A, Pickering A, Williams P, Bland JM, Johnson MJ. Breathlessness and presentation to the emergency department: a survey and clinical record review. BMC Pulm Med. 2017;17(1):53.CrossRefGoogle Scholar
  31. Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002;57(11):939–44.CrossRefGoogle Scholar
  32. Johnson M, Bowden J, Abernethy AP, Currow DC. To what causes do people attribute their chronic breathlessness? A population survey. J Palliat Med. 2012;15(7):744–50.CrossRefGoogle Scholar
  33. Johnson MJ, Bland JM, Oxberry SG, Abernethy AP, Currow DC. Opioids for chronic refractory breathlessness: patient predictors of beneficial response. Eur Respir J. 2013;42(3):758–66.CrossRefGoogle Scholar
  34. Johnson MJ, Simpson MI, Currow DC, Millman RE, Hart SP, Green G. Magnetoencephalography to investigate central perception of exercise-induced breathlessness in people with chronic lung disease: a feasibility pilot. BMJ Open. 2015;5(6):e007535.CrossRefGoogle Scholar
  35. Johnson MJ, Yorke J, Hansen-Flaschen J, Lansing R, Ekström M, Similowski T, Currow DC. Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness. Eur Respir J. 2017;49(5): 1602277.CrossRefGoogle Scholar
  36. Jones PW, Quirk FH, Baveystock CM. The St George’s respiratory questionnaire. Respir Med. 1991;85:25–31.CrossRefGoogle Scholar
  37. Karakontaki F, Gennimata S-A, Palamidas AF, et al. Driving-related neuropsychological performance in stable COPD patients. Pulm Med. 2013;2013:Article ID 297371.CrossRefGoogle Scholar
  38. King MD, Meuser TM, Berg-Weger M, et al. Decoding the Miss Daisy syndrome: an examination of subjective responses to mobility change. J Gerontol Soc Work. 2011;54(1):29–52.CrossRefGoogle Scholar
  39. Luckett T, Disler R, Hosie A, Johnson M, Davidson P, Currow D, Sumah A, Phillips J. Content and quality of websites supporting self-management of chronic breathlessness in advanced illness: a systematic review. NPJ Prim Care Respir Med. 2016;26:16025.CrossRefGoogle Scholar
  40. Luckett T, Phillips J, Johnson MJ, Garcia M, Bhattarai P, Carrieri-Kohlman G, Hutchinson A, Disler RT, Currow D, Agar M, Ivynian S, Chye R, Newton PJ, Davidson PM. Insights from Australians with respiratory disease living in the community with experience of self-managing through an emergency department ‘near miss’ for breathlessness: a strengths-based qualitative study. BMJ Open. 2017;7(12):e017536.CrossRefGoogle Scholar
  41. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984;85(6):751–8.CrossRefGoogle Scholar
  42. Mailis-Gagnon A, Lakha SF, Furlan A, et al. Systematic review of the quality and generalizability of studies on the effects of opioids on driving and cognitive/psychomotor performance. Clin J Pain. 2012;28(6):542–55.CrossRefGoogle Scholar
  43. Marciniuk DD, Goodridge D, Hernandez P, Rocker G, Balter M, Bailey P, Ford G, Bourbeau J, O’Donnell DE, Maltais F, Mularski RA, Cave AJ, Mayers I, Kennedy V, Oliver TK, Brown C, Canadian thoracic society COPD Committee Dyspnea Expert Working Group. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2011;18(2):69–78.CrossRefGoogle Scholar
  44. Marottoli RA, de Leon CFM, Glass TA, et al. Consequences of driving cessation decreased out-of-home activity levels. J Gerontol B Psychol Sci Soc Sci. 2000;55(6):S334–S40.CrossRefGoogle Scholar
  45. McDonald CF, Crockett AJ, Young IH. Adult domiciliary oxygen therapy. Position statement of the Thoracic Society of Australia and New Zealand. Med J Aust. 2005;182(12):621–6.PubMedGoogle Scholar
  46. Mezuk B, Rebok GW. Social integration and social support among older adults following driving cessation. J Gerontol B Psychol Sci Soc Sci. 2008;63(5):S298–303.CrossRefGoogle Scholar
  47. Nilsen HK, Landrøl NI, Kaasal S, et al. Driving functions in a video simulator in chronic non-malignant pain patients using and not using codeine. Eur J Pain. 2011;15(4):409–15.CrossRefGoogle Scholar
  48. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121(5): 1434–40.CrossRefGoogle Scholar
  49. Nishino T. Dyspnoea underlying mechanisms and treatment. Br J Anaesth. 2011;106(4):463–74.CrossRefGoogle Scholar
  50. Peiffer C, Poline JB, Thivard L, Aubier M, Samson Y. Neural substrates for the perception of acutely induced dyspnea. Am J Respir Crit Care Med. 2001;163(4): 951–7.CrossRefGoogle Scholar
  51. Peoples AR, Bushunow PW, Garland SN, Heckler CE, Roscoe JA, Peppone LL, Dudgeon DJ, Kirshner JJ, Banerjee TK, Hopkins JO, Dakhil SR. Buspirone for management of dyspnea in cancer patients receiving chemotherapy: a randomized placebo-controlled URCC CCOP study. Support Care Cancer. 2016;24(3):1339–47.CrossRefGoogle Scholar
  52. Ries AL. Minimally clinically important difference for the UCSD shortness of breath questionnaire, borg scale, and visual analog scale. COPD. 2005;2(1):105–10.CrossRefGoogle Scholar
  53. Rocker G, Young J, Donahue M, Farquhar M, Simpson C. Perspectives of patients, family caregivers and physicians about the use of opioids for refractory dyspnea in advanced chronic obstructive pulmonary disease. CMAJ. 2012;184(9):E497–504.CrossRefGoogle Scholar
  54. Rocker GM, Simpson AC, Young J, Horton R, Sinuff T, Demmons J, Donahue M, Hernandez P, Marciniuk D. Opioid therapy for refractory dyspnea in patients with advanced chronic obstructive pulmonary disease: patients’ experiences and outcomes. CMAJ Open. 2013;1(1):E27–36.CrossRefGoogle Scholar
  55. Simon ST, Bausewein C, Schildmann E, Higginson IJ, Magnussen H, Scheve C, Ramsenthaler C. Episodic breathlessness in patients with advanced disease: a systematic review. J Pain Symptom Manag. 2013;45(3):561–78.CrossRefGoogle Scholar
  56. Simon ST, Higginson IJ, Booth S, Harding R, Bausewein C. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2016;10:CD007354.Google Scholar
  57. Sjøgren P, Olsen A, Thomsen A, et al. Neuropsychological performance in cancer patients: the role of oral opioids, pain and performance status. Pain. 2000;86(3):237–45.CrossRefGoogle Scholar
  58. Tarpy SP, Celli BR. Long-term oxygen therapy. N Engl J Med. 1995;333(11):710–4.CrossRefGoogle Scholar
  59. Uronis HE, Currow DC, McCrory DC, Samsa GP, Abernethy AP. Oxygen for relief of dyspnoea in mildly-or non-hypoxaemic patients with cancer: a systematic review and meta-analysis. Br J Cancer. 2008;98(2):294–9.CrossRefGoogle Scholar
  60. Uronis HE, Ekström MP, Currow DC, McCrory DC, Samsa GP, Abernethy AP. Oxygen for relief of dyspnoea in people with chronic obstructive pulmonary disease who would not qualify for home oxygen: a systematic review and meta-analysis. Thorax. 2015;70(5):492–4.CrossRefGoogle Scholar
  61. von Leupoldt A, Sommer T, Kegat S, Baumann HJ, Klose H, Dahme B, Büchel C. The unpleasantness of perceived dyspnea is processed in the anterior insula and amygdala. Am J Respir Crit Care Med. 2008;177(9):1026–32.CrossRefGoogle Scholar
  62. Watts GJ, Clark K, Agar M, Davidson PM, McDonald C, Lam LT, Sajkov D, McCaffrey N, Doogue M, Abernethy AP, Currow DC, On behalf of the Australian national Palliative Care Clinical Studies Collaborative (PaCCSC). Study protocol: a phase III randomised, double-blind, parallel arm, stratified, block randomised, placebo controlled trial investigating the clinical effect and cost-effectiveness of sertraline for the palliative relief of breathlessness in people with chronic breathlessness. BMJ Open. 2016;6:e013177.  https://doi.org/10.1136/bmjopen-2016-013177.CrossRefPubMedPubMedCentralGoogle Scholar
  63. Weingärtner V, Scheve C, Gerdes V, Schwarz-Eywill M, Prenzel R, Otremba B, Mühlenbrock J, Bausewein C, Higginson IJ, Voltz R, Herich L, Simon ST. Characteristics of episodic breathlessness as reported by patients with advanced chronic obstructive pulmonary disease and lung cancer: results of a descriptive cohort study. Palliat Med. 2015;29(5):420–8.CrossRefGoogle Scholar
  64. Weir N, Fischer A, Good P. Assessing the practice of palliative care doctors–what driving advice do they give patients with advanced disease? Intern Med J. 2017;47(10):1161–5.CrossRefGoogle Scholar
  65. Widman A, Bergstrom S. Driving for patients in palliative care-a reality? Springerplus. 2014;3:79.  https://doi.org/10.1186/2193-1801-3-79.CrossRefPubMedPubMedCentralGoogle Scholar
  66. Wilcock A, Crosby V, Clarke D, Tattersfield A. Repeatability of breathlessness measurements in cancer patients. Thorax. 1999;54:374.CrossRefGoogle Scholar
  67. Williams M, Cafarella P, Olds T, Petkov J, Frith P. The language of breathlessness differentiates between patients with COPD and age-matched adults. Chest. 2008;134(3):489–96.CrossRefGoogle Scholar
  68. Wiseman RL, Rowett D, Allcroft P, Abernethy AP, Currow DC. Chronic refractory dyspnoea – evidence based management. Aust Fam Phys. 2013;42(3): 137–40.Google Scholar
  69. Young J, Donahue M, Farquhar M, Simpson C, Rocker G. Using opioids to treat dyspnea in advanced COPD: attitudes and experiences of family physicians and respiratory therapists. Can Fam Physician. 2012;58(7):e401–7.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.IMPACCT – Improving Palliative Aged Care through Clinical Research and Translation, Faculty of HealthUniversity of Technology SydneyUltimoAustralia
  2. 2.Wolfson Palliative Care Research Centre, Hull York Medical SchoolUniversity of HullHullUK
  3. 3.Flinders UniversityBedford ParkAustralia

Personalised recommendations